Respiratory Endoscopy
Online ISSN : 2758-3813
Case Report
Recurrent Idiopathic Tracheal Stenosis Treated with Sequential Endoscopic Tracheoplasty for Two Different Modalities: A Case Report
Atsushi NakaseMasahide OkiAkihiko MatsuuraAya ShirahigeYusuke TsushimaNozomi GotoMari TanakaMasayasu InagakiYuta KodamaRyota ItoToshihiko Yokoyama
Author information
JOURNAL OPEN ACCESS

2024 Volume 2 Issue 3 Pages 167-172

Details
Abstract

Idiopathic tracheal stenosis is an extremely rare disease that can constrict the airway, with no established therapeutic strategy. We herein present our experience with a patient with recurrent idiopathic tracheal stenosis treated with sequential endoscopic tracheoplasty using different modalities. A 41-year-old woman presented with dyspnea and wheezing 6 years ago, which gradually worsened over time. Chest computed tomography revealed tracheal stenosis caused by fold-like structures 15 mm below the glottis. Spirometry results indicate central airway stenosis. Bronchoscopy revealed significant tracheal stenosis due to a circumferentially protruding web-like structure. Pathological tissue biopsy revealed nonspecific inflammation and granulation. The patient was diagnosed with idiopathic tracheal stenosis in the absence of any obvious alternative causes. Argon plasma coagulation (APC) therapy was performed because of severe dyspnea and decreased peak flow. Her dyspnea and pulmonary function improved immediately after treatment. Follow-up bronchoscopy after 6 months revealed significant improvement in the stenosis; however, the lesion recurred 10 months after treatment. Therefore, tracheoplasty using a cryoprobe and balloon dilatation was performed as a second treatment, resulting in another successful improvement. Endoscopic tracheoplasty using APC or cryoprobe is effective for idiopathic tracheal stenosis, thereby enabling the selection of treatment strategies at each facility.

Content from these authors
© 2024 The Japan Society for Respiratory Endoscopy

This article is licensed under a Creative Commons [Attribution 4.0 International] license.
https://creativecommons.org/licenses/by/4.0/
Previous article Next article
feedback
Top